key: cord-0696030-04owg5ry authors: O’Carroll, Shane Myles; O’Neill, Luke A J title: Targeting immunometabolism to treat COVID-19 date: 2021-06-02 journal: Immunother Adv DOI: 10.1093/immadv/ltab013 sha: bf07e6675af9f57826a42ef9fdc2ae3d4e75b418 doc_id: 696030 cord_uid: 04owg5ry The COVID-19 crisis has emphasised the need for antiviral therapies to combat current and future viral zoonoses. Recent studies have shown that immune cells such as macrophages are the main contributors to the inflammatory response seen in the later inflammatory phase of COVID-19. Immune cells in the context of a viral infection such as SARS-CoV-2 undergo metabolic reprogramming to elicit these pro-inflammatory effector functions. The evidence of metabolic reprogramming in COVID-19 offers opportunities for metabolites with immunomodulatory properties to be investigated as potential therapies to combat this inflammatory response. Recent research indicates that the metabolite itaconate, previously known to be broadly antibacterial, may have both antiviral and immunomodulatory potential. Furthermore, low itaconate levels have shown to correlate with COVID-19 disease severity, potentially implicating its importance in the disease. The antiviral potential of itaconate has encouraged researchers to synthesise itaconate derivatives for antiviral screening, with some encouraging results. This review summarises the antiviral and immunomodulatory potential of immunometabolic modulators including metformin, PPAR agonists and TEPP-46 as well as itaconate, and its derivatives and their potential use as a broad spectrum anti-viral agents. The innate immune system is our immune system's first line of defence against viruses, such as SARS-CoV-2. It consists of a set of germline-encoded pathogen recognition receptors (PRRs) that function to recognise pathogen-associated molecular patterns (PAMPS). For viral recognition, these PRRs consist of toll-like receptors (TLRs), RIG-I-like receptors (RLRs), NOD-like receptors (NLRs), and DNA sensors. Each sense conserved molecular structures in viruses (largely nucleic acid-based) and induce intracellular signalling cascades which converge on transcription factor activation and subsequent transcription of genes encoding pro-inflammatory cytokines, chemokines, and type 1 interferons to regulate the immune response, induce inflammation and limit viral replication (1). Apart from the well-known innate immune signalling triggered by a viral infection, metabolic change also occurs downstream of some of these sensors. This was first discovered in response to LPS from gram-negative bacteria. LPS activation of toll-like receptor 4 pathway upregulates aerobic glycolysis and fatty acid synthesis with a concomitant reduction in mitochondrial respiration and β-oxidation in macrophages. Breakpoints occur in the tricarboxylic acid cycle (TCA) cycle after succinate and citrate, causing these metabolites to accumulate. The accumulation of citrate drives mitochondrial ROS (mtROS), nitric oxide accumulation, itaconate production and contributes to the pro-inflammatory phenotype of M1-like macrophages (2) . Citrate accumulation also causes acetyl-CoA to build up and contributes to epigenetic changes such as histone acetylation, facilitating transcription of inflammatory genes (3). Accumulation of succinate drives Warburg-like metabolism and acts by inhibiting prolyl hydroxylases, thus increasing hypoxia-inducible factor 1-alpha (HIF1⍺) stabilisation. This drives glycolysis and also increases transcription of the pro-inflammatory cytokine interleukin 1 β (IL-1β). Succinate accumulation also causes reverse electron transport (RET) causing mtROS production and the stabilisation of HIF1⍺ (4, 5) . During viral infection the host undergoes two phases of response, the first phase is a proinflammatory viral limiting response and the second phase is the resolution and anti-inflammatory phase. Both phases are important to effective viral clearance and host recovery from infection, and mal-adaptive responses in either phase can result in pathologies not directly related to viral load or viral effects, but the immunopathology caused by cells of the immune system (6) . Given the importance of macrophages in both phases of the immune response and the demonstrated metabolic flexibility modulating macrophage phenotype this review focuses on the metabolic reprogramming and immunological response to metabolic modulation and metabolites as a potential therapeutic avenue to the treatment of the pathogenic inflammation associated with COVID-19. Protein 5A (NS5A) from HCV binds and activates hexokinase, a rate-limiting glycolytic enzyme, to increase glycolytic rate (8) . Creating this Warburg-like metabolism also contributes to the production of type 1 interferons and inflammatory cytokines which aid in the anti-viral immune response (9) . Viral infection often activates HIF1⍺ which contributes to anti-viral innate immunity by producing inflammatory mediators. However, HIF1⍺ also upregulates glycolytic genes needed for virion replication and therefore benefits the virus (10) . Many viruses also modulate other metabolic pathways such as downregulating mitochondrial β-oxidation and upregulating fatty acid synthesis to aid virus envelopment for the release of the virus (11). The progression from SARS-CoV-2 infection to severe COVID-19 is caused by a mal-adaptive immune response which is defined by failure to elicit a timely and robust type-1 interferon innate immune response. This leads to increased viral load, followed by a hyperinflammatory immune response, such as acute phase reactants and inflammatory markers such as interleukin 6 (IL-6), Tumor necrosis factor (TNF), IL1β, and interleukin 18 (IL-18) (12) . This bi-phasic nature of COVID-19 progression to severe disease, the early viral phase followed by the inflammatory phase, suggests that antiinflammatory therapies would be suited to those who present later in the infection and have persistently increased inflammatory markers. Monocytes and macrophages are the most abundant immune cell-types in SARS-CoV-2-infected lungs and contribute to hyper-inflammatory cytokine production evident in severe COVID-19 (13) . SARS-CoV-2 infects many cell types including airway epithelial cells and macrophages. Infection of macrophages causes metabolic reprogramming, similar to that created by LPS, causing an increase in aerobic glycolysis, reduction of the TCA cycle and RET (14) . This metabolic reprogramming is mediated by the production of mtROS, stabilisation of HIF1⍺ and HIF1⍺-mediated transcription of core glycolytic genes involved in glucose import and glycolysis including Glucose transporter 1 (GLUT-1), Pyruvate kinase M2 (PKM2), Lactate dehydrogenase A (LDH-A) and 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3). It has also been shown that lactate dehydrogenase, an important enzyme in Warburg metabolism in M1-like macrophages, is a prognostic marker of disease severity in COVID-19 and further highlights the role of glycolysis in COVID-19 (15) . Ex-vivo experiments using human monocytes from SARS-CoV-2 infected patients showed that HIF1⍺ protein was significantly increased when compared to uninfected patients. In -vitro experiments with SARS-CoV-2-infected human monocytes elegantly demonstrate that elevated glucose levels and glycolysis facilitates SARS-CoV-2 replication, as blocking glycolysis inhibits viral replication. Furthermore, the increased glycolysis also increases the production of IL-1β which contributes to the hyperinflammatory response of COVID-19. These in-vitro experiments directly implicate HIF1⍺ in viral replication and inflammatory cytokine production as HIF1⍺ inhibition was shown to inhibit SARS-CoV-2 replication and HIF1⍺ activation increased viral replication. Furthermore, HIF1⍺ inhibition also blocked transcription of inflammatory cytokines associated with severe COVID19 including IL1β, TNF, IL6, interferon alpha (IFN⍺), interferon beta (IFNβ) and Angiotensinconverting enzyme 2 (ACE2) (14) . This makes compelling evidence for targeting mtROS-HIF⍺-metabolic reprogramming as a potential treatment of severe COVID-19 by inhibiting viral replication and the inflammatory cytokines seen in COVID-19 pathology (14) . Given these metabolic features, and the discovery that low plasma itaconate levels correlate with COVID-19 disease severity, it seems likely that itaconate might play a role in COVID-19 (16) . Itaconate is a metabolite produced by the decarboxylation of the TCA cycle intermediate cis- aconitate, a reaction catalysed by aconitate decarboxylase 1 (ACOD1), also referred to as immune responsive gene 1 (IRG1) (17, 18) . IRG1 and itaconate have been closely associated with the metabolic reprogramming of macrophages in-vitro into an M1-like phenotype as IRG1 is one of the most upregulated genes in classically activated macrophages (19) . The main role of itaconate in macrophages is to act in a negative feedback fashion, limiting inflammation (20) . Notably, itaconate is also antibacterial against many pathogens including Salmonella enterica and Mycobacterium tuberculosis (Mtb). These bacteria use carbon sources produced by the glyoxylate shunt to survive during human infection. Itaconate inhibits this glyoxylate shunt via blocking a key enzyme isocitrate lyase. Itaconate also stops Mtb from using carbon sources from cholesterol degradation by inhibiting Mtb mediated detoxification of propionic acid (21) . As well as being anti-bacterial, itaconate is also immunomodulatory. Biochemically, itaconate has been shown to alkylate cystine residues, resulting in changes to protein structure and binding. invitro experiments have shown that exogenous itaconate treatment of bone-marrow-derived macrophages upregulates IFN-β in a yet undetermined mechanism (22) . Also, itaconate and it's An interesting link from itaconate to SARS-CoV-2 was recently reported. 4-OI, a derivative of itaconate, has been shown to activate nuclear factor-erythroid factor 2-related factor 2 (NRF2) via the alkylation of Kelch Like ECH Associated Protein 1 (KEAP1) (28) . Furthermore, NRF2 activation is impaired in IRG-1 deficient macrophages treated with LPS. Of note, itaconate has the ability to restore LPS-induced NRF2 activation in IRG-1 deficient macrophages (29, 30) . This is interesting as NRF2 functions as a transcription factor that binds to the promoter region of pro-inflammatory genes, preventing RNA Polymerase II binding and also inhibits the transcription of pro-inflammatory cytokines IL6 and IL1β in macrophages (31) . NRF2 also drives antioxidant genes which reduce mtROS and HIF1⍺ mediated inflammation. Transcriptome analysis of severe COVID-19 patients has shown that NRF2 dependant genes are suppressed including Heme Oxygenase 1 (HMOX1) and NAD(P)H Quinone Dehydrogenase 1 (NqO1) (32) . This suggests that these NRF2 activators could be used as therapies for COVID-19. Mitochondrial dysfunction and the production of mtROS are common features of SARS-CoV-2 infection in human macrophages ex-vivo and in vivo and causes the stabilisation of HIF1⍺ and the following production of pro-inflammatory cytokines (14) . This mechanism has also been seen in SARS-CoV-1 studies demonstrating that nucleocapsid protein N disrupts mitochondrial membrane potential and increases mtROS in-vitro (35) . Furthermore, SARS-CoV-2 infection of bronchial epithelial cells reduces mitochondrial gene expression, leading to mitochondrial dysfunction and increasing mtROS in-vitro (36) . Proteins involved in mitochondrial fission are also suppressed, increasing mitochondrial fusion and which impairs antiviral interferon responses (37) . With this in mind, MitoQ is a mitochondria-specific antioxidant that increases autophagy and reduces mtROS in-vitro and in murine models (38) . Additionaly, studies demonstrate that MitoQ has antiviral potential. In vivo mouse models have shown that MitoQ reduce dextran sulfate sodiuminduced colitis by reducing inflammatory cytokines IL-1β, TNF, and mtROS (39, 40) . Furthermore, in- MitoQ suppresses RSV viral infection by blocking mitochondrial dysfunction and mtROS production (39, 41) . Importantly, an in-vitro study using SARS-CoV-2 infection of human monocytes shows that MitoQ blocks SARS-CoV-2 replication, and reduces HIF1⍺ stabilisation and inflammatory cytokine IL-1β and ACE2 (14) Increased glycolysis is also associated with SARS-CoV-2 replication. PKM2 is an enzyme that catalyses the final step of glycolysis and also has important roles in immune cell reprogramming and inflammation. However, PKM2 activity depends on its oligomerisation state. PKM2 tetramers are inactive, whereas phosphorylation of PKM2 forms a dimer that enters the nucleus, binds HIF1⍺, and causes the expression of proinflammatory and glycolytic genes (42) . In the context of COVID-19, both PKM2 levels and phosphorylated PKM2 levels increase with COVID-19 severity. This indicates that PKM2 is important in COVID-19 severity via activation of HIF1⍺ and the expression of inflammatory cytokines (43) . This metabolic reprogramming causes cytosolic succinate accumulation which activates HIF1⍺. This is supported by ex-vivo COVID-19 studies show succinate levels and nuclear translocation of both HIF1⍺ and PKM2 positively correlate with COVID-19 disease severity (43) . Maintaining PKM2 as a tetramer could therefore be a potential therapy for COVID-19. Compounds such as TEPP-46 maintain PKM2 in a tetramer, inhibiting Warburg-like metabolism, succinate accumulation, inflammatory cytokine IL-1β and inhibits HIF1⍺ dependant transcription of glycolytic genes needed for SARS-CoV-2 (44). Other potential immunomodulators being proposed for the treatment of COVID-19 include Metformin is a safe, widely used glucose lowering agent used to treat type 2 diabetes mellitus (T2DM). The anti-viral potential of metformin was first discovered in the 1940s when it showed significant anti-influenza properties (49) . Metformin has been shown to block ZIKA virus replication, increase innate immune signalling via interferon-stimulated genes such as interferon stimulated gene 15 (ISG15), 2'-5'-Oligoadenylate Synthetase 2 (OAS2) and blocks TNF and CCL5 production invitro and in-vivo (50) . Metformin significantly reduced hospital mortality in diabetic patients with COVID-19, suggesting therapeutic potential (51) . Metformin's anti-viral effect could be attributed to several potential mechanisms. SARS-CoV-2 entry into cells causes the downregulation of ACE2. ACE2 downregulation dysregulates the rennin-angiotensin system (RAS) which may contribute to increased inflammation. potentially preventing RAS dysregulation and reducing inflammation (52) . Furthermore, In human endothelial cells, metformin causes increased phosphorylation of ACE2 Ser680 via AMPK. This might suggest that ACE2 phosphorylation might block spike-ACE2 interaction or binding and therefore reduce SARS-CoV-2 cell entry (53) . Metformin also blocks IL1β production and increases the antiinflammatory cytokine IL-10 and inhibits complex 1 in mitochondria, indicating its anti-inflammatory potential for COVID-19 (40) . Furthermore, neutrophil extracellular traps (NETs) contribute to the immunopathology seen in COVID-19 (54) . Metformin inhibits NETs in diabetic patients (55) . Metformin has also been shown to block mechanistic target of rapamycin (mTOR). Sirolimus, another mTOR inhibitor has been shown to block MERS-CoV infection in vitro and significantly improve ICU patient outcome (56, 57) . Clinical trials investigating mTOR inhibitors against COVID-19 are currently recruiting participants. Metformin might have potential as a therapy for COVID-19. Dimethyl fumarate (DMF) is a common therapy for adult patients with relapsing-remitting multiple sclerosis (58, 59) . Studies suggest that DMF might have a similar mechanism of action as itaconate by activating NRF2 and target enzymes in glycolysis (60) . DMF inhibits SARS-CoV-2 replication and replication of other viruses such as VACV, Zika virus, HSV1/2 in an interferon independent mechanism (32) . DMF also suppresses inflammatory responses seen in severe COVID-19 by both liberating NRF2 and inhibiting the NF-κB signalling pathway by preventing p65 nuclear translocation. This has been shown to inhibit the transcription of inflammatory cytokines IFNB1, CXCL10, and CCL5 gene expression and upregulation of anti-inflammatory genes HMOX1 (32) (61) . Furthermore, activating NRF2 also blocks transmembrane protease serine 2 (TMPRSS2) expression, which is needed for ACE2-mediated cell penetration of SARS-CoV-2 via the spike protein (62, 63) . Given that DMF is an approved medication further research on whether it reduces severity of COVID19 is warranted. Viral sensing by PRRs causes interferon production, while increased glycolysis and FAS induces inflammatory cytokine production. Macrophages can be infected by SARS-CoV-2 in the same mechanism or can be polarised by inflammatory cytokines produced by airway epithelial cells. M1-like polarisation of macrophages causes the production of inflammatory cytokines that contribute to the immunopathology seen in COVID-19. Created with Biorender.com Host genetic susceptibility to viral infections: the role of type I interferon induction A guide to immunometabolism for immunologists Toll-like Receptor Signaling Rewires Macrophage Metabolism and Promotes Histone Acetylation via ATP-Citrate Lyase Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages Immunity and immunopathology to viruses: what decides the outcome? Stealing the Keys to the Kitchen: Viral Manipulation of the Host Cell Metabolic Network Activity of hexokinase is increased by its interaction with hepatitis C virus protein NS5A Cutting Edge: Critical Role of Glycolysis in Human Plasmacytoid Dendritic Cell Antiviral Responses Contribution of hypoxia inducible factor-1 during viral infections Metabolic host response and therapeutic approaches to influenza infection Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis Itaconic acid is a mammalian metabolite induced during macrophage activation Immuneresponsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation Itaconate: an emerging determinant of inflammation in activated macrophages Itaconic Acid: The Surprising Role of an Industrial Compound as a Mammalian Antimicrobial Metabolite Comparative evaluation of itaconate and its derivatives reveals divergent inflammasome and type I interferon regulation in macrophages The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients Toll or interleukin-1 receptor (TIR) domain-containing adaptor inducing interferon-β (TRIF)-mediated caspase-11 protease production integrates Toll-like receptor 4 (TLR4) protein-and Nlrp3 inflammasome-mediated host defense against enteropathogens The Nucleotide Sensor ZBP1 and Kinase RIPK3 Induce the Enzyme IRG1 to Promote an Antiviral Metabolic State in Neurons Differential innate immune response programs in neuronal subtypes determine susceptibility to infection in the brain by positive-stranded RNA viruses Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1 Electrophilic properties of itaconate and derivatives regulate the IκBδ-ATF3 inflammatory axis Itaconate confers tolerance to late NLRP3 inflammasome activation Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and antiinflammatory activity of 4-octyl-itaconate and dimethyl fumarate Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogramming Synthesis, and Biological Evaluation of Itaconic Acid Derivatives as Potential Anti-Influenza Agents SARS-CoV nucleocapsid protein induced apoptosis of COS-1 mediated by the mitochondrial pathway Master Regulator Analysis of the SARS-CoV-2/Human Interactome Network Analysis and Transcriptome Profiling Identify Autophagic and Mitochondrial Dysfunctions in SARS-CoV-2 Infection Targeting antioxidants to mitochondria by conjugation to lipophilic cations Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines Metformin Inhibits the Production of Reactive Oxygen Species from NADH:Ubiquinone Oxidoreductase to Limit Induction of Interleukin-1β (IL-1β) and Boosts Interleukin-10 (IL-10) in Lipopolysaccharide (LPS)-activated Macrophages Subversion of Host Cell Mitochondria by RSV to Favor Virus Production is Dependent on Inhibition of Mitochondrial Complex I and ROS Generation HIF1α and metabolic reprogramming in inflammation Characterization of the Inflammatory Response to Severe COVID-19 Illness Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties Role of NF-kappaB and PPAR-gamma in lung inflammation induced by monocyte-derived microparticles Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19 PPARγ Cistrome Repression during Activation of Lung Monocyte-Macrophages in Severe COVID-19. iScience Metformin: historical overview AMP-Activated Protein Kinase Restricts Zika Virus Replication in Endothelial Cells by Potentiating Innate Antiviral Responses and Inhibiting Glycolysis Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications AMPK: a balancer of the reninangiotensin system Targeting potential drivers of COVID-19: Neutrophil extracellular traps NETosis before and after Hyperglycemic Control in Type 2 Diabetes Mellitus Patients Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety Placebocontrolled phase 3 study of oral BG-12 for relapsing multiple sclerosis Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein Nrf1 and Nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor